Index
Bibliographic record
Abstract
abacavir 443 abdominal examination 6-7 ascites 214 cholestasis 246 jaundice 246 pancreatic cancer 304 abdominal wall veins 162-3, 162, 163 ablation therapy for HCC 693, 694 abscesses amoebic see amoebiasis pyogenic see pyogenic liver abscess recurrent pyogenic cholangitis 349, 655 acaeruloplasminaemia 530 acanthocytes (spur cells) 48-9, 49 accessory lobe 4 acetaldehyde 507-8, 509 acetaminophen poisoning see paracetamol poisoning acetylcholine 137 N-acetylcysteine (NAC) 84 aciclovir 85, 433 acidosis in ALF 82 lactic acidosis syndrome 448, 495 acinus, hepatic functional heterogeneity of hepatocytes 15-16, 15 structure 9, 9, 10 actinomycosis 638-9 acute fatty liver of pregnancy (AFLP) 603-5, 603, 604 overlap with toxaemia 607, 607 acute heart failure 198 acute intermittent porphyria 627 acute liver failure (ALF) 70-89 in Budd-Chiari syndrome 74, 193 causes drugs 72-3, 73, 482 hepatitis 71-2 other 73-4, 73 worldwide differences 72 in children/neonates galactosaemia 583 mitochondrial disorders 584-5, 711 neonatal haemochromatosis 531, 583-4 classifi cation 71 clinical features 74-5 complications cerebral oedema 79-81, 81 coagulopathy 81-2 encephalopathy 70-1, 77-9, 81 gastrointestinal haemorrhage 83-4 hypotension 83 infections 82-3 metabolic abnormalities 82 pancreatitis 84 pulmonary 84 renal 83 defi nition 70-1 diagnosis biochemistry 30, 75-6, 75, 583 biopsy 76-7, 78 EEG 76, 76 imaging 76, 77 hepatitis (autoimmune) 74, 76, 85 hepatitis (viral) 71-2, 75, 84-5, 356-7, 380 mushroom poisoning 73-4, 84 paracetamol poisoning 72-3, 75-6, 84, 482 in pregnancy 71-2, 74, 86-7 prognosis 70, 74, 86, 87, 569, 583 treatment artifi cial liver support 88, 89 of complications 77, 79-81, 80, 82, 83, 84 of hepatitis 84, 380 hepatocyte transplantation 88 liver transplantation 82, 85, 86-8, 87, 711 of mushroom poisoning 84 of neonatal haemochromatosis 584 of paracetamol poisoning 84 of Wilson's disease 86 Wilson's disease 74, 76, 86, 537-8, 538 acute phase proteins 31 acyclovir 85, 433 Addison's disease 623 adefovir 384, 386 dosage 386 in HBV/HIV coinfection 440 pretransplant 733 resistance 385, 386, 389 response rates 383 adenocarcinoma bile duct (cystadenocarcinoma) 302, 676 gallbladder 294-7 see also pancreatic cancer adenofi broma, bile duct 676 adenoma bile duct 676 hepatocellular 671-3 in children 596 clinical features 672-3 diagnosis 46, 667, 673 histopathology 672, 672 treatment 673 adenomyomatosis of the gallbladder 277 adenosine receptors 137-8 S-adenosyl-L-methionine 250 adenovirus 724 adiponectin 555 adrenal gland, ectopic 678 afl atoxin 682 AFLP see acute fatty liver of pregnancy AFP (α-fetoprotein) 32, 686-7 African iron overload 531 age autoimmune hepatitis 455, 469 drug-related liver injury 34, 484 gallstones 265 HAV immunity 360, 362 HBV treatment 382 hepatocellular carcinoma 682 jaundice 245 liver function 33-4 Wilson's disease 537 agenesis, right lobe 4 AIDS acute cholecystitis 278-9 AIDS cholangiopathy 349, 446 see also HIV (human immunodefi ciency virus) AIH see autoimmune hepatitis Alagille's syndrome 577-8, 578, 709 alanine aminotransferase (ALT) 23, 568 in drug-induced liver injury 488 in hepatitis B 378, 440 albendazole 652 albuferon (alphaferon) 423 albumin assessment of liver function 31, 31, 32 replacement after paracentesis 222 serum-ascites albumin gradient 215 treatment of HRS 226, 228 treatment of SBP 217 alcohol autoimmune hepatitis and 463 cancer and 510, 510 Note: Page numbers in italic refer to fi gures and/or tables antinuclear antibodies (ANA) in autoimmune hepatitis 457 in PBC 333 α 1 -antitrypsin defi ciency 462, 576-7, 576, 710 antiviral therapy for CMV 433 for EBV 433 for HBV 383 acute infections 84 in children 586 combination therapy 387, 735 dose regimens 384, 386 drug resistance 384-5, 385, 386, 387, 388 fi rst-line therapies 386-7, 387, 609 in HIV-positive patients 439-40, 440, 609 initiation 380-2, 381 interferon 382-4, 386-7, 388, 440 nucleos(t)ide analogues 383, 384-9, 439-40, 440, 733-5, 741 post-transplant 708, 733-5, 734, 741 in pregnancy 609 pretransplant 708, 733, 733 rescue therapies 388-9, 389 side effects 384, 386 termination 388 for HCV abbreviated regimes 418-19, 442 acute infections 411-12 in children 586 combination therapy (IFN/ RBV) 415-20, 416, 419, 441-2, 443 in HIV-infected patients 441-4, 442, 443 indications for 415, 441 non-responders 419-20 post-transplant prophylaxis/preemptive therapy 738, 739 post-transplant recurrent disease 738, 739-40, 739, 740 pretransplant 738-9, 738 research targets 420-3, 420, 421, 422, 443-4 virological response rates 416-18, 417, 419, 442, 443 for HDV 401 combination therapy 402 goals 400-1 in HIV-infected patients 444 interferon 401-2, 402-3 nucleoside analogues 401, 402 prenylation inhibitors 403 for HHV-6 434 for HIV (HAART) in HBV-positive patients 439-40 in HCV-positive patients 442-3 liver damage and 446-8, 447, 494-5, 494 for SARS-coronavirus 435 aplastic anaemia 50, 357 hepatitis-associated 427 apolipoproteins 26, 27 amyloidosis 624 apoptosis, hepatic 17, 17, 486 in drug-induced liver injury 485-7 in NASH 554 see also necrosis, hepatic
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.002 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.001 | 0.000 |
| Scholarly communication | 0.003 | 0.002 |
| Open science | 0.001 | 0.002 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.778 | 0.623 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".